BioLife Solutions Acquires PanTHERA CryoSolutions

BioLife Solutions Acquires Stirling Ultracold

March 22, 2021

Manufacturing

BioLife Solutions, Inc. agreed to acquire Global Cooling, Inc., operating as Stirling Ultracold, in an all-stock merger in which BioLife will issue 6,646,870 shares to acquire 100% of Stirling. The deal (expected to close in early Q2 2021) expands BioLife's cold-chain and ULT freezer product portfolio, adds Stirling’s ~150 employees and IP, and is expected to be accretive on an adjusted net income per share basis in 2022 and beyond.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

BioLife Solutions Acquires SciSafe

September 21, 2020

Healthcare Services

BioLife Solutions, Inc. (NASDAQ: BLFS) has entered into a definitive agreement to acquire SciSafe, a privately held multi-facility biostorage provider serving the cell and gene therapy and pharmaceutical industries. BioLife will pay $15 million cash and $15 million in newly issued BioLife common shares for 100% of SciSafe, with up to 626,000 additional shares earnable based on revenue milestones; the deal is expected to close on September 30.

1315 Capital Acquires SciSafe from BioLife Solutions

November 14, 2024

Healthcare Services

1315 Capital, a Philadelphia-based growth equity firm, has acquired SciSafe from BioLife Solutions in an all-cash transaction that establishes SciSafe as an independent, standalone biostorage company. The deal accompanies a growth capital investment to fund expansion of SciSafe's biostorage, cold-chain and compliance capabilities and to support global footprint growth.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.